Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen

Simple item page
dc.contributor.authorTarek, Nidale
dc.contributor.authorHayes-Jordan, Andrea A.
dc.contributor.authorSalvador, Laura K.
dc.contributor.authorMcAleer, Mary Frances
dc.contributor.authorHerzog, Cynthia Elaine
dc.contributor.authorHuh, Winston W.
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:47Z
dc.date.available2025-01-24T12:10:47Z
dc.date.issued2018
dc.description.abstractDesmoplastic small round cell tumor (DSRCT) is a rare mesenchymal tumor that typically presents with multiple abdominal masses. Initial treatment is multimodal in nature. Patients with relapsed DSRCT have a poor prognosis, and there are no standard therapies. We report our experience with five patients treated with vinorelbine, cyclophosphamide, and temsirolimus (VCT). Median number of VCT courses delivered was 7 (range 4–14 courses), and partial response was observed in all patients. Median time to progression or relapse was 8.5 months (range 7–16 months). Neutropenia and mucositis were most common toxicities (n = 4 each). © 2017 Wiley Periodicals, Inc.
dc.identifier.doihttps://doi.org/10.1002/pbc.26768
dc.identifier.eid2-s2.0-85030175104
dc.identifier.pmid28941151
dc.identifier.urihttp://hdl.handle.net/10938/32424
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc.
dc.relation.ispartofPediatric Blood and Cancer
dc.sourceScopus
dc.subjectChildhood cancer
dc.subjectDesmoplastic
dc.subjectRecurrence
dc.subjectSarcoma
dc.subjectTemsirolimus
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAntineoplastic combined chemotherapy protocols
dc.subjectChild
dc.subjectCyclophosphamide
dc.subjectDesmoplastic small round cell tumor
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMucositis
dc.subjectNeoplasm recurrence, local
dc.subjectNeutropenia
dc.subjectSirolimus
dc.subjectVinblastine
dc.subjectCarboplatin
dc.subjectCreatinine
dc.subjectDacarbazine
dc.subjectDactinomycin
dc.subjectDoxorubicin
dc.subjectEpirubicin
dc.subjectEtoposide
dc.subjectFluorodeoxyglucose f 18
dc.subjectGemcitabine
dc.subjectIfosfamide
dc.subjectIrinotecan
dc.subjectMammalian target of rapamycin inhibitor
dc.subjectPaclitaxel
dc.subjectTemozolomide
dc.subjectVincristine
dc.subjectVinorelbine tartrate
dc.subjectAntineoplastic agent
dc.subjectRapamycin
dc.subjectAbdomen
dc.subjectAbdominal cancer
dc.subjectArticle
dc.subjectCancer combination chemotherapy
dc.subjectClinical article
dc.subjectClinical assessment
dc.subjectCreatinine blood level
dc.subjectCytoreductive surgery
dc.subjectDrug megadose
dc.subjectFatigue
dc.subjectFever
dc.subjectHuman
dc.subjectKidney injury
dc.subjectLiver cancer
dc.subjectLiver metastasis
dc.subjectMaintenance chemotherapy
dc.subjectMucosa inflammation
dc.subjectMultimodality cancer therapy
dc.subjectObservational study
dc.subjectPelvis cancer
dc.subjectPositron emission tomography-computed tomography
dc.subjectPriority journal
dc.subjectRetrospective study
dc.subjectSchool child
dc.subjectTumor growth
dc.subjectTumor recurrence
dc.subjectAnalogs and derivatives
dc.subjectChemically induced
dc.subjectClinical trial
dc.subjectDiagnostic imaging
dc.titleRecurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2018-8589.pdf
Size:
736.71 KB
Format:
Adobe Portable Document Format
Download

Collections

Pediatrics and Adolescent Medicine